Mahzi Therapeutics Inc. — Form D/A
Mahzi Therapeutics Inc. of South San Francisco, CA, a company, filed a Form D amendment with the SEC on 2022-11-14. The offering totals $47.3M, of which $47.3M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-11-14
- Form: D/A
- Accession: 0001888808-22-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $47.3M
- Amount sold: $47.3M
- Investors: 10
- Date of first sale: 2021-10-07
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-417994
Issuer
- Name: Mahzi Therapeutics Inc.
- CIK: 0001888808
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 470 Noor Ave, STE B, #1036, South San Francisco, CA, 94080
- Phone: 415-627-8781
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Shalini Sharp | Director | San Diego, CA |
| Camille Samuels | Director | South San Francisco, CA |
| Stephen Farr | Director | South San Francisco, CA |
| Marten Steen | Director | Lausanne, V8 |
| Yael Weiss | Director | South San Francisco, CA |
| Yael Weiss | Executive Officer | South San Francisco, CA |
Other filings by this issuer (2)
More